iRhythm's Q2 Leap: 20% Growth plus Bigger Portfolio Has Investors Repricing the Margin Story

iRhythm is starting to look like a growth business with improving economics

This quarter matters because iRhythm is beginning to look less like a medical-device growth story that needs continuous spending to stay ahead. Q2 showed revenue up 20.1% to $224.2 million, adjusted EPS of $0.58 versus a zero consensus, and a 19.3% adjusted EBITDA margin. That combination shifts the conversation from whether demand would keep building to how much of that growth can convert into profit.

The growth story was already there; the margin story is improving

This was the company's seventh consecutive quarter of revenue growth above 20%, so the demand story was not new. What changed was the operating leverage. Gross margin improved 160 basis points to 72.8%, while operating expenses remained essentially flat at about $145 million. In simple terms, iRhythm is putting more tests through a more efficient operating model, which is why investors are beginning to focus more on earnings power than on top-line growth alone.

One quarter does not close the case. The VitalConnect acquisition will bring integration work, and guidance still has to hold. But the bullish case is stronger because fast growth and better margins appeared in the same report.

Volume growth and workflow gains are supporting the margin expansion

The better question is not whether iRhythm can sell more tests. It is how the company is handling more tests without a matching rise in costs. Management said volume remained the primary driver of growth, and the mix matters. About 45% of year-over-year volume growth came from new accounts, suggesting demand is widening rather than relying only on the existing base. At the same time, several large accounts added earlier have moved into same-store growth, which points to deeper business from existing customers as well.

Workflow tools are helping more tests move through a similar cost base

That mix matters for margins because iRhythm is not only processing more volume; it is doing so more efficiently. Gross margin improved year over year, driven by manufacturing automation, workflow optimization, and scale benefits. Adjusted operating expenses remained essentially flat, which suggests the company generated more activity without spending much harder.

A concrete example is the software update. The FDA cleared iRhythm's third-generation algorithm, which is expected to reduce clinical technician review time by up to 50% and generate roughly $100 million in cumulative cost savings over five years. That does not create demand by itself, but it should help lower the cost to process each additional test over time.

Portfolio expansion widens the funnel, while execution remains the key test

There is also a broader distribution story. Management said the innovative channel was the fastest-growing segment, which helps explain part of the new-account contribution and makes growth less dependent on traditional cardiology alone.

The main watchpoint is whether iRhythm can keep operating discipline as it funds growth and integrates new capabilities. Flat operating expenses helped Q2, but future cash conversion still depends on not spending those efficiency gains away.

What to watch next: - Whether new-account growth remains healthy - Whether review-time gains translate into lasting labor savings - Whether volume growth continues to outpace headcount and operating expense growth

Full-year guidance is now the real test of the quarter

One strong quarter captured attention. The harder test is whether investors see a repeatable improvement in earnings power rather than a single clean print. iRhythm delivered Q2 results that exceeded revenue expectations, posted $0.58 adjusted EPS versus a zero consensus, and received a strong positive market reaction. The stock has already responded, so the decision now is whether forward guidance gives investors a credible bridge to more profit in 2026.

Revenue guidance and margin targets matter more than the headline quarter

Management now expects roughly $885 million in full-year revenue and an adjusted EBITDA margin of 13% to 14%. That margin target is the key number. If it holds, investors can justify building more earnings power into their model. If it slips, critics will argue the Q2 margin breakout was more about timing than lasting structure.

The next proof points

The next few updates matter more than another recap of Q2: - sustained volume growth across cardiology, primary care, and innovative channels - continued gross-margin support from automation and workflow gains - evidence that the VitalConnect acquisition complements rather than complicates the margin story

What would weaken the thesis

This view weakens if: - growth becomes more dependent on new accounts while existing accounts stall - operating expenses rise quickly as the company funds expansion - the company misses its 13% to 14% adjusted EBITDA margin target

Q2 looked like a proof of concept. The next few quarters need to show that it was also a step toward a more efficient business model.